Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 7, 2019

View Archived Issues

Same compound inhibits wild-type, activates mutant MALT1

Membrane rips kill axons in MS

Transcriptional CDK inhibitors downregulate brachyury in chordoma

PVRIG and TIGIT regulate CD8+ T cells/tumor cells interaction and can be a target for immunotherapy

REST-regulated gene secretagogin as a novel prognostic biomarker in prostate cancer

New cyclopeptides containing N-methyl amino acids with activity against several P. falciparum stages

Denali enzyme therapy for MPS II crosses the blood-brain barrier

University of Texas System divulges ATR kinase inhibitors

MEK/ERK2 pathway regulates Shank3 stability: a novel target for SHANK3-related disorders

ArmaGen arylsulfatase A fusion protein shows promise for metachromatic leukodystrophy

Misplaced energy turns T cells proinflammatory

Positive results announced from phase I study of LY-3056480 in sensorineural hearing loss

Updated clinical data presented from ongoing studies of AVR-RD-01 gene therapy for Fabry disease

Early cardiac hypertrophy seen in murine model of Pompe disease

FDA approves Cablivi for treatment of aTTP

Inhibrx begins first-in-human study of INBRX-105 bispecific antibody for cancer

U.S. researchers present new compounds for tuberculosis

ProtNeteomix identifies new EGFR degradation inducers

Evotec and Galapagos collaborate on small-molecule fibrotic disease program

Sichuan Haisco Pharmaceutical describes kappa-opioid receptor agonists

ReViral presents RSV fusion inhibitors as new antivirals

Axsome reaches SPA agreement with FDA on phase III trial for AXS-07 for acute migraine

Arch Oncology initiates phase I trial of AO-176 in select solid tumors

Roche conducts phase I trial of RO-7239958 for chronic HBV infection

Solid seeks to escalate dose in IGNITE DMD trial of SGT-001 following preliminary findings

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026